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Abstract
Background: The prevention of mother to child transmission of HIV has resulted in reduced burden of
pediatric HIV-infection, but the prevalence of maternal HIV infection remains high in sub-Saharan African
countries. HIV-exposed-uninfected infants have an increased risk of morbidity and mortality due to infectious
diseases than HIV-unexposed infants, particularly during the first six months of life, which in part might be
due to lower levels of pathogen-specific protective antibodies acquired transplacentally from their mothers.
This could be mitigated by vaccinating pregnant women to boost antibody levels; although vaccine responses among
HIV-infected pregnant women might differ compared to HIV-uninfected women. We reviewed studies that compared
natural and vaccine-induced antibody levels to different epitopes between HIV-infected and HIV-uninfected pregnant
women.
Findings: Most studies reported lower baseline/pre-vaccination antibody levels in HIV-infected pregnant women,
which may not be reversed by antiretroviral therapy during pregnancy. There were only few studies on vaccination of
HIV-infected pregnant women, mainly on influenza virus and group B Streptococcus (GBS) vaccines. Immunogenicity
studies on influenza vaccines indicated that HIV-infected pregnant women had lower vaccine induced hemagglutination
inhibition antibody titers and a decreased likelihood of seroconversion compared to HIV-uninfected women; and while
higher CD4+ T-lymphocyte levels were associated with better immune responses to vaccination, HIV viral load was not
associated with responses. Furthermore, infants born to influenza vaccinated HIV-infected pregnant women also had
lower antibody levels and a lower proportion of HIV-exposed infants had titers above the putative correlate of protection
compared to HIV-unexposed infants. The immunogenicity of a CRM197-conjugated trivalent GBS vaccine was also lower in
HIV-infected pregnant women compared to HIV-uninfected women, irrespective of CD4+ T-lymphocyte counts.
Conclusions: Poorer immunogenicity of vaccines reported in HIV-infected compared to HIV-uninfected pregnant women
might compromise the potential benefits to their young infants. Alternate vaccination strategies, including vaccines
with higher antigen concentration, adjuvanted vaccines or multiple doses schedules might be required in HIV-infected
pregnant women to optimize antibody transferred to their fetuses.
Keywords: Pregnant women, HIV, Antibody, Immunity, Vaccine
* Correspondence: ziyaad.dangor@wits.ac.za
1Medical Research Council: Respiratory and Meningeal Pathogens Research
Unit, University of the Witwatersrand, Johannesburg, South Africa
2Department of Science and Technology/National Research Foundation:
Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg,
South Africa
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Dangor et al. Tropical Diseases, Travel Medicine and Vaccines  (2017) 3:1 
DOI 10.1186/s40794-016-0044-7
Background
HIV-exposed infants, a new vulnerable population
Advances in the prevention of mother to child transmis-
sion (PMTCT) of HIV-1 infection have substantially de-
creased the prevalence of pediatric HIV-infection and the
burden of HIV attributable-childhood infectious diseases,
including in high prevalence sub-Saharan African countries
[1]. Nevertheless, the prevalence of HIV among pregnant
women remains high in many African countries, and
there is emerging recognition of higher morbidity and
mortality among HIV-exposed uninfected (HEU) than
HIV-unexposed young infants [2–4]. Marinda et al.
reported a 2.8-fold (95% CI: 2.1–3.9) and 5.5-fold
(95% CI: 3.9–7.9) higher mortality rate among HEU
compared to HIV-unexposed infants from birth to
two months, and from two to six months of age, re-
spectively [5]. Furthermore, HEU infants under six
months of age have a 2.7-fold increased risk of inva-
sive Streptococcus pneumoniae disease and 2.3-fold in-
creased risk of invasive group B Streptococcus (GBS)
disease [6, 7], which correlates to the degree of maternal
immunosuppression [8]. Additionally, HEU compared to
HIV-unexposed infants have 1.4-fold increased risk for
hospitalization for common respiratory virus associated
pneumonia, including respiratory syncytial virus and hu-
man metapneumovirus [9] (Table 1).
The possible mechanisms for the increased susceptibility
of HEU infants to infectious diseases were recently
reviewed [3, 4, 10]. This included lower levels of pathogen-
specific protective antibodies among HIV-infected women
and reduced efficiency of transplacental transfer of anti-
bodies. The lower epitope-specific antibody concentrations
against vaccine preventable diseases in HIV-infected
women [11–13], is likely due to HIV-induced loss of mem-
ory T- and B-lymphocyte function. Furthermore, placental
abnormalities and saturation of active transport receptors
may also result in inefficient transplacental antibody trans-
fer to fetuses of HIV-infected women [10]. Compounding
this might be immune dysregulation such as T-cell activa-
tion, increased pro-inflammatory cytokines secretion, and
increased lymphocyte apoptosis in HEU infants [10].
Reduced thymic sizes and lower CD4+ T-lymphocyte
counts were also observed in HEU infants. Although not
clearly understood, in-utero antiretroviral therapy (ART)
exposure has been associated with mitochondrial toxicity,
lower numbers of circulating T-cell lymphocytes and neu-
trophils in young infants [10].
Maternal vaccination as a strategy to prevent infant
disease
Vaccination during pregnancy could potentially improve
maternal and child health [14], as already shown by the ef-
fectiveness of vaccination during pregnancy with tetanus
toxoid vaccine in reducing mortality from neonatal tet-
anus in low-middle income countries by >80% from prox-
imately 1.27 million cases in the 1980s to <50,000 cases by
2013 [15]. Also, in the USA and some European countries,
maternal vaccination strategies have been adopted for the
prevention of influenza and pertussis in the women and
their young infants [16]. There is growing public aware-
ness about the benefits of maternal vaccination; with 72%
of women in the United Kingdom considering vaccination
during pregnancy as acceptable [17].
The protection of the infants could either be due to
prevention of mother-to-child transmission of pathogens
during close contact, or through transfer of maternal
epitope-specific protective antibodies via the placenta
and/or breastmilk. This is especially beneficial against
diseases presenting soon after birth, or during the initial
vulnerable period prior to young infants completing
their immunization against vaccine preventable diseases
[12]. The effectiveness of vaccination of pregnant
women in protecting their infants through transplacental
antibody transfer depends on a number of factors such
as: (i) the immunogenicity of the vaccine among preg-
nant women, (ii) baseline maternal antibody levels and
underlying prevalence of memory lymphocytes, (iii) sub-
class of the antibodies induced by the vaccine, (iv) effi-
ciency of transplacental antibody transfer, (v) adequate
gestational time to allow for optimal in-utero transpla-
cental transfer of antibodies, and (vi) antibody half-life
in the women and infant [18].
Table 1 Incidence ratio ratio’s and mortality in HIV-exposed and –unexposed infants less than 6 months of age
Year Incidence (95% CI) per 100 000 Incidence rate ratio (95% CI) Mortality risk
HIV-exposed HIV-unexposed
Invasive disease
Streptococcus pneumoniae [6] 2013 57 (46–71) 21 (17–36) 2.7 (2.0–3.7) 1.8 (1.1–2.9)a
Streptococcus agalactiaeb [7] 2004–2008 4.5 (3.9–5.1) 2.0 (1.7–2.3) 2.3 (1.9–2.8) -
Lower respiratory tract associated hospitalization
Respiratory syncytial virus [9] 2010–2011 5003 (4505–5541) 3507 (3244–3787) 1.4 (1.3–1.5) 2.1 (1.1–3.8)c
Human metapneumovirus [9] 2010–2011 816 (622–1050) 573 (470–692) 1.4 (1.1–2.0) -
aadjusted relative risk ratio in HEU infants (37% [59/175]) versus HIV-unexposed infants (32% [51/228]) for 2009 and 2013; bLess than 3 months of age; cOdd ratio
of death in HEU versus HIV-unexposed infants
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The transplacental acquired antibodies in the fetus are
almost exclusively IgG antibodies, with more efficient
and abundant transfer of IgG1 compared to IgG2 [18].
IgG2 is preferentially induced by polysaccharide epi-
topes, used in many vaccines against encapsulated or-
ganisms such as Streptococcus pneumoniae, GBS and
Haemophilus influenzae type b; whereas IgG1 is induced
primarily by protein epitopes [14, 18]. The transfer of
maternal antibodies across the placenta is via an active
transport mechanism utilizing Fc receptors [19]. To
transfer from the maternal to the fetal circulation, IgG
need to cross over the syncytiotrophoblast and the fetal
endothelium [20]. Factors that might influence this
transplacental antibody transfer include placental integ-
rity, the IgG subclass, maternal nutritional status, parity/
gravidity and gestational age [11, 14, 21].
Vaccination during pregnancy aimed at protecting the
infants, needs to induce sufficient maternal antibody
levels that will be transferred to the fetus within the
remaining gestational period; and persist in the infant
through early infancy. The active transfer of maternal
IgG antibodies (natural or vaccine-induced) occurs most
efficiently in the third trimester of pregnancy [22]. Infant
to maternal antibody ratios are variable for different an-
tigens, estimates generally range between 75 to 135% at
term (≥37 weeks), 50–95% at 33–36 weeks, and 30–55%
at 28–32 weeks gestation age [22–24]. Although a more
efficient transfer of antibodies occurs in the last weeks
before birth, infants born to women vaccinated in the
second trimester had higher levels of pertussis anti-
bodies than those vaccinated in the third trimester [25].
Generally, maternal and cord blood antibody concentra-
tions are correlated; though higher maternal antibody
concentrations and more efficient transplacental transfer
are noted in mothers in high-income countries com-
pared to low-income countries [11, 26]. This difference
is most probably attributable to the higher prevalence of
chronic maternal infections, placental infections or un-
dernutrition in low-income countries [11, 27].
Maternal HIV-infection and vaccination
Generally, HIV-infected pregnant women have lower
baseline/pre-vaccination antibody levels, including to
epitopes of measles virus, influenza virus, Streptococcus
pneumoniae, Haemophilus influenzae type b, GBS and
tetanus compared to HIV-uninfected women [11–13, 21,
28–30]. This is most likely due to a loss of epitope-
specific T- and B-memory cells caused by the immuno-
suppressive progression of HIV-infection. Because most
HIV-infected women of child-bearing age in low-middle
income countries are only initiated on ART during preg-
nancy [1], the net loss of epitope-specific memory might
already have occurred in those with more advanced dis-
ease and therefore late-ART initiation may not result in
complete immune reconstitution [31]. An association
between higher maternal CD4+ T-lymphocyte counts
and maternal antibody baseline levels has been observed
in women [12]. Therefore, unless the immune-status is
preserved by early-ART, HIV-infected pregnant women
will likely have lower pre-vaccination/baseline antibody
levels and might mount poorer booster responses to vac-
cination [32] (Fig. 1).
This could be further compounded by reduced transpla-
cental antibody transfer in HIV-infected compared to
HIV–uninfected mother-newborn dyads (Fig. 1). HIV-
infection is associated with a hyper-gammaglobulinemia
state which might result in saturation of the Fc receptors,
hence impeding antibody transfer to the fetus [20]. Studies
have reported lower newborn to maternal antibody ratios
for measles, varicella, tetanus, Haemophilus influenzae,
pertussis and pneumococcus antibodies in HIV-infected
compared to HIV-uninfected mother-newborn dyads [12,
13, 20, 21, 33]. Although a South African study did not
identify an association between transplacental anti-
body transfer and CD4+ T-lymphocyte counts or
HIV-1 viral load [12]; high maternal HIV-1 viral load
was reported to reduce transplacental antibody transfer in
another study [34].
Influenza vaccine and HIV-infected pregnant women
HIV-exposed uninfected infants less than six months have
an increased risk of hospitalization and death from respira-
tory virus-associated lower respiratory tract infections,
including influenza virus [2, 9]. In South Africa, two
double-blind, randomized, placebo-controlled trials evalu-
ated the safety, immunogenicity and efficacy of a trivalent
influenza vaccine in HIV-infected and HIV-uninfected
pregnant women, including follow-up of their infants until
six months of age [35]. Vaccination of pregnant women
with a trivalent influenza vaccine has proven to be safe for
both the women and their infants [35]. Before vaccination
and one month post-vaccination with the trivalent influ-
enza vaccine, HIV-infected compared to HIV-uninfected
pregnant women, had lower hemagglutination-inhibition
(HAI) antibody titers and a decreased likelihood of sero-
conversion (41% vs. 92%, respectively to at least one strain)
[30]. Similar observations were reported from a smaller
study in the USA, where increased regulatory T-cells num-
bers were associated with attenuated immune responses to
influenza vaccination in HIV-infected women, resulting in
reduced immunogenicity to at least one influenza vaccine
strain despite similar pre-vaccination HAI titers compared
to HIV–uninfected women [36]. Interestingly, high pre-
vaccine HAI titers correlated with lower seroconversion
rates in HIV-uninfected women, whereas, high pre-vaccine
titers correlated with improved seroconversion rates in
HIV-infected women [30]. Correlation analyses of post-
vaccination HAI titers and HIV viral load in HIV-infected
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pregnant women, most of whom were on ART, generally
have not shown any association [30, 36–38]. Improved im-
mune responses were, however, detected against at least
one strain in the trivalent influenza vaccine in women with
CD4+ T-lymphocyte counts of >350 cells/μL [30].
After vaccination with an unadjuvanted 2009 pan-
demic H1N1 monovalent influenza vaccine, HAI titers
were also significantly increased in women with higher
CD4+ T-lymphocyte counts [37, 38]. In the study of the
2009 pandemic, H1N1 monovalent influenza vaccination of
130 HIV-infected pregnant women, a second dose of a
high-concentration (30 μg/dose) vaccine marginally im-
proved the percentage of women with HAI titers above the
putative seroprotective threshold of ≥1:40 and who demon-
strated seroconversion (73% and 66% after dose 1 and 80%
and 72% after dose 2, respectively). Nevertheless, HIV-
infected women still had poorer immune responses than
described in HIV-uninfected women [38]. Furthermore,
non-pregnant HIV-infected adults had in general poorer
immune responses to standard dose (15 μg) of unadju-
vanted influenza vaccines compared to HIV-uninfected in-
dividuals [39–42].
The inferior immune response to unadjuvant inactivated
influenza vaccines in HIV-infected adults has led to inves-
tigation for alternate strategies to improve the immune re-
sponses to vaccination in this population. Influenza
vaccines with higher antigen content elicited higher HAI
titers and improved seroresponse rates in HIV-infected
non-pregnant adults, however, the responses were still in-
ferior compared to HIV-uninfected adults [43, 44]. Fur-
thermore, a second vaccine dose did not consistently
increase the immune responses [40, 41, 43, 45]. Although
the safety and immunogenicity of adjuvanted pandemic
H1N1 vaccines has not been evaluated in HIV-infected
pregnant women, immune responses in non-pregnant
HIV-infected adults were better with adjuvanted pan-
demic H1N1 vaccine compared to unadjuvanted vaccines;
this included higher percentage of ASO3-adjuvanted vac-
cine recipients developing HAI titers ≥1:40 compared to
unadjuvanted vaccine–recipients [41]. HAI titers ≥1:40
were 70–93% and increased to 94–99% after 2 doses of
the ASO3-adjuvanted vaccine, which was similar to the
response described in HIV-uninfected individuals (>95%)
[41, 46]. Also, a single dose of a MF59-adjuvanted vaccine
was associated with 88% of HIV-infected adults develop-
ing HAI titers ≥1:40, which had a small increase to 91%
following the second vaccination, which was similar to
HIV-uninfected controls [47]. Overall, the HAI GMT ti-
ters were, however, lower in HIV-infected than HIV-
uninfected adults [47].
Among the newborns of HIV-infected women, birth
HAI titers correlated strongly with maternal antibody ti-
ters at delivery [30, 38]. A comparison between HIV-
infected and HIV-uninfected pregnant women vaccinated
with trivalent influenza vaccine reported lower transpla-
cental HAI antibody transfer in HIV-infected women for
only one of the three vaccine strains [30]. Nevertheless,
due to the lower HAI titers post-vaccination among HIV-
infected pregnant women, their newborns had lower HAI
antibody titers and were less likely to have HAI titers
≥1:40 compared to HIV-unexposed infants (ranging from
43–79% vs. 82–95%, respectively for the different vaccine
Fig 1 Proposed differences in vaccine-induced antibody responses between HIV-infected and –uninfected mother-infant pairs. Footnote: HIV-infected
women [red dotted], HIV-uninfected women [dark blue], HIV-exposed infant [maroon dotted], HIV-unexposed infant [light blue]
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strains) [30]. Despite the antibody half-life being longer in
HIV-exposed (56–65 days) than in HIV-unexposed infants
(43–45 days) [30], seroprotective levels did not persist in
most infants beyond three months of age [38, 48] (Fig. 2).
No direct comparison is available for infant HAI titers
after maternal H1N1 monovalent influenza vaccination be-
tween HIV-exposed than in HIV-unexposed infants [38].
In healthy adults, a HAI titer of 1:40 or higher is asso-
ciated with 50% protection against influenza disease
[49]. However, data from studies on HIV-infected preg-
nant and non-pregnant adults suggest that influenza vac-
cination may confer protection to this population by
additional mechanisms and that the use of HAI titers as
a correlate of protection needs to be validated in these
individuals [30, 50]. Furthermore it has been proposed
that higher HAI titers may be required to provide pro-
tection against influenza in children [51].
In the South African randomized-controlled trials of tri-
valent influenza vaccine in pregnant women, the vaccine
efficacy against PCR-confirmed influenza was similar in
HIV-infected (58%; 95% CI: 0.2, 82) and HIV-uninfected
(50%; 95% CI: 15, 71) women despite HIV-infected
women having a reduced immune response to vaccination
[30, 35]. Two other randomized-controlled trials evaluated
the efficacy of trivalent influenza vaccine in pregnant
women against influenza infection in the women and their
infants until six months of age; however, the only study
that measured vaccine efficacy in HIV-infected women
was conducted in South Africa [35, 52, 53]. Incidentally,
the trial conducted in Bangladesh reported fewer episodes
of influenza infection during the first six months of life in
infants born to influenza vaccinated pregnant women
compared to infants born to women who received 23-
valent pneumococcal vaccine; for laboratory confirmed in-
fluenza infection in infants the vaccine efficacy was 63%
(95% CI: 5, 85) [52]. The two other larger African trials
corroborated the protection afforded by maternal vaccin-
ation against PCR–confirmed influenza in infants younger
than six months. In Mali infants born to women who re-
ceived influenza vaccine had a lower influenza attack-rate
compared to those born to women vaccinated with quadri-
valent meningococcal vaccine, with an overall vaccine effi-
cacy of 33% (95% CI: 4, 54) [53]. In South Africa the
vaccine efficacy against PCR–confirmed influenza was 49%
(95% CI: 12, 70) among infants born to HIV-uninfected
women and while the study was not powered to detect vac-
cine efficacy in the HIV-exposed infants a modest vaccine
efficacy point estimate was reported (26.7%; CI: −132, 77)
[35]. Based on the immunogenicity data from the two
South African trials, despite vaccine efficacy in the
HIV-infected mothers (which was similar compared to
HIV-uninfected women), alternate strategies to protect
the HIV-exposed infants need to be considered. Whilst
vaccine induced cell mediated immunity might play a role
in adults, protection in the infants will only be mediated
by the presence of antibodies; hence higher antibody con-
centrations need to be elicited in the women.
Group B Streptococcus and maternal HIV-infection
Although recto-vaginal GBS colonization is similar or
lower in HIV-infected compared to HIV-uninfected preg-
nant women [54–56], HEU have a 2–20 fold increase sus-
ceptibility of invasive GBS disease compared to HIV-
unexposed infants; and particularly so for late-onset
disease (disease occurring from 7 to 89 days of life,
LOD; 4–125 fold) [7, 57, 58]. Furthermore, HEU
compared to HIV-unexposed infants with invasive
GBS disease are more likely to present with menin-
gitis than sepsis [58].
Natural serotype-specific and surface-protein IgG anti-
bodies have been compared between HIV-infected and
HIV-uninfected mother-newborn dyads [28, 29]. In two
studies conducted in two different regions of South Africa
with a high HIV prevalence, serotypes Ia, Ib, II, III and
V-specific IgG antibody levels were consistently lower in
HIV-exposed compared to HIV–unexposed newborns
[28, 29]. This was likely due to the combination of lower
maternal antibody concentrations and reduced transpla-
cental antibody transfer between HIV-infected compared
to HIV-uninfected mother-newborn pairs. Both studies,
Fig. 2 a, b, c Percentage of HIV-exposed and –unexposed infants with seroprotective antibody titers against the three influenza strains after their
mothers had been vaccinated with influenza vaccine during pregnancy. Data from the maternal influenza South African clinical trial [50]
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although not specifically powered to address the question,
reported no associations between the maternal level of im-
mune suppression and anti-GBS epitope antibody levels
or transplacental ratios, although most women had CD4+
T-lymphocyte counts >350 cells/mL and were on ART
during pregnancy [28, 29]. Furthermore, another recent
study from South Africa showed that the proportion of in-
dividual IgG subclasses transferred through the placenta
was unaffected by maternal HIV infection, with the excep-
tion of serotypes III IgG1; and importantly there was no
difference in transplacental transfer of IgG2, the main sub-
class against GBS polysaccharides [59].
Maternal GBS vaccination is potentially cost effective,
both in high income [60, 61] and low-middle income
countries [62]. Early experimental conjugate vaccines in-
duced good IgG responses in pregnant women which
persisted for long periods and could also protect against
LOD [63, 64]. Although there is no licensed GBS vaccine,
an investigational trivalent GBS polysaccharide-protein
conjugate vaccine that includes serotypes Ia, Ib and III was
recently evaluated in a phase-II study among HIV-
uninfected and HIV-infected pregnant women [65, 66]. In
Malawi (18% maternal HIV prevalence) and South African
(30% maternal HIV prevalence), lower vaccine immuno-
genicity was observed among the HIV-infected compared
to HIV-uninfected pregnant women [66]. Among HIV-
infected women, immune responses did not differ between
those with low (50–350 cells/mL) and high (>350 cells/mL)
CD4+ T-lymphocyte counts. Furthermore, antibody con-
centrations post-vaccination were lower in women without
detectable antibody levels at baseline, suggesting an ab-
sence of memory lymphocytes in these women. Transpla-
cental antibody transfer and antibody decay was similar
between HIV-infected and HIV-uninfected mother-
newborn dyads, nevertheless, HIV-exposed infants had
lower antibody concentrations than HIV-unexposed infants
at birth and at 6 weeks of age [66]. Because a correlate of
protection has not been established, it is unknown whether
antibody concentrations in HIV-exposed infants are suffi-
cient to protect against invasive GBS disease.
Conclusions
Antibody transfer from mother to fetus is crucial in pro-
tecting young infants against various infectious diseases
prior to their primary immunization or during the
period that they are unable to mount a robust immune
response to infection. Poor immune responses to natural
infection result in lower antibody levels in HIV-infected
women and may contribute to disease susceptibility in
HIV-exposed infants. Although maternal vaccination re-
duces early infant disease, lower immune responses to
vaccines have been reported in HIV-infected compared
to HIV-uninfected pregnant women; this needs to be
considered in vaccine development, especially in settings
with high maternal HIV-infection prevalence and re-
gardless of PMTCT or ART. Females who were born
with HIV and those on long-term ART would soon be
entering child-bearing age; these women need to be fur-
ther studied as to whether T- and B-cell memory is
preserved.
Immunogenicity may be enhanced in HIV-infected
women through two-dosing vaccine schedules [38]. The
first dose would “re-prime” the HIV-infected women’s im-
mune system and then the second dose would serve as a
booster. Higher antigen concentrations and the use of con-
jugate vaccines have also shown improved immunogen-
icity and efficacy in HIV-infected adults and may be
explored in HIV-infected pregnant women [38, 67]. The
use of adjuvants to boost immune responses needs further
investigation. Maternal vaccine immunogenicity studies or
phase IV efficacy trials, coupled with cost-effectiveness
studies must be conducted in HIV-infected pregnant
women in highly endemic settings.
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